Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CEL-SCI Corp announces closing of public offering for gross proceeds of $10 mln

Thursday, 17 Apr 2014 11:55am EDT 

CEL-SCI Corp:Closes underwritten public offering of units consisting of aggregate of 7,128,229 shares of common stock and warrants to purchase an aggregate of 1,782,057 shares of common stock.Units sold at $1.40 per unit and resulted in aggregate gross proceeds of about $10 mln.Intends to use the net proceeds for its Phase III head and neck cancer clinical trial, other research and development, and general and administrative expenses.Dawson James Securities, Inc. and Laidlaw & Company (UK) Ltd. acted as joint book-running managers and underwriters for the offering. 

Company Quote

-0.06 -5.83%
6 May 2015